

Vittorio Bellotti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1762639/publications.pdf>

Version: 2024-02-01

179
papers

10,706
citations

41344

49
h-index

34986

98
g-index

185
all docs

185
docs citations

185
times ranked

8902
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Mechanisms of Amyloidosis. <i>New England Journal of Medicine</i> , 2003, 349, 583-596.	27.0	1,629
2	Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. <i>Nature</i> , 1997, 385, 787-793.	27.8	1,061
3	Targeting C-reactive protein for the treatment of cardiovascular disease. <i>Nature</i> , 2006, 440, 1217-1221.	27.8	621
4	Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. <i>Nature</i> , 2010, 468, 93-97.	27.8	290
5	Removal of the N-terminal hexapeptide from human β_2 -microglobulin facilitates protein aggregation and fibril formation. <i>Protein Science</i> , 2000, 9, 831-845.	7.6	263
6	Rapid Proton-Detected NMR Assignment for Proteins with Fast Magic Angle Spinning. <i>Journal of the American Chemical Society</i> , 2014, 136, 12489-12497.	13.7	254
7	Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 2959-2963.	7.1	198
8	Review: Immunoglobulin Light Chain Amyloidosis – The Archetype of Structural and Pathogenic Variability. <i>Journal of Structural Biology</i> , 2000, 130, 280-289.	2.8	179
9	Hereditary Systemic Amyloidosis Due to Asp76Asn Variant β_2 -Microglobulin. <i>New England Journal of Medicine</i> , 2012, 366, 2276-2283.	27.0	172
10	The solution structure of human β_2 -microglobulin reveals the prodromes of its amyloid transition. <i>Protein Science</i> , 2002, 11, 487-499.	7.6	145
11	A Partially Structured Species of β_2 -Microglobulin Is Significantly Populated under Physiological Conditions and Involved in Fibrillogenesis. <i>Journal of Biological Chemistry</i> , 2001, 276, 46714-46721.	3.4	137
12	Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1570-1583.	3.8	134
13	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. <i>Blood</i> , 1995, 86, 855-861.	1.4	128
14	Collagen Plays an Active Role in the Aggregation of β_2 -Microglobulin under Physiopathological Conditions of Dialysis-related Amyloidosis*. <i>Journal of Biological Chemistry</i> , 2006, 281, 16521-16529.	3.4	128
15	Structure, function and amyloidogenic propensity of apolipoprotein A-I. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2006, 13, 191-205.	3.0	124
16	Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology. <i>Molecular Therapy</i> , 2019, 27, 2111-2122.	8.2	120
17	Detection of two partially structured species in the folding process of the amyloidogenic protein β_2 -microglobulin. <i>Journal of Molecular Biology</i> , 2001, 307, 379-391.	4.2	115
18	A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. <i>EMBO Molecular Medicine</i> , 2015, 7, 1337-1349.	6.9	109

#	ARTICLE	IF	CITATIONS
19	The New Apolipoprotein A-I Variant Leu174 → Ser Causes Hereditary Cardiac Amyloidosis, and the Amyloid Fibrils Are Constituted by the 93-Residue N-Terminal Polypeptide. <i>American Journal of Pathology</i> , 1999, 155, 695-702.	3.8	108
20	Heparin Strongly Enhances the Formation of β 2-Microglobulin Amyloid Fibrils in the Presence of Type I Collagen. <i>Journal of Biological Chemistry</i> , 2008, 283, 4912-4920.	3.4	108
21	Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic β 2-microglobulin variant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 1314-1319.	7.1	108
22	β 2-microglobulin can be refolded into a native state from <i>ex vivo</i> amyloid fibrils. <i>FEBS Journal</i> , 1998, 258, 61-67.	0.2	107
23	Biological activity and pathological implications of misfolded proteins. <i>Cellular and Molecular Life Sciences</i> , 1999, 55, 977.	5.4	102
24	Amyloidogenesis in its biological environment: challenging a fundamental issue in protein misfolding diseases. <i>Current Opinion in Structural Biology</i> , 2008, 18, 771-779.	5.7	100
25	Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. <i>Arthritis and Rheumatism</i> , 2009, 61, 1435-1440.	6.7	100
26	Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1539-1544.	7.1	91
27	Effect of Tetracyclines on the Dynamics of Formation and Deconstruction of β 2-Microglobulin Amyloid Fibrils. <i>Journal of Biological Chemistry</i> , 2011, 286, 2121-2131.	3.4	87
28	Conformational Switching and Fibrillogenesis in the Amyloidogenic Fragment of Apolipoprotein A-I. <i>Journal of Biological Chemistry</i> , 2003, 278, 2444-2451.	3.4	86
29	The Controlling Roles of Trp60 and Trp95 in β 2-Microglobulin Function, Folding and Amyloid Aggregation Properties. <i>Journal of Molecular Biology</i> , 2008, 378, 887-897.	4.2	82
30	A novel β 2PP mutation exclusively associated with cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2005, 58, 639-644.	5.3	81
31	Structure, Folding Dynamics, and Amyloidogenesis of D76N β 2-Microglobulin. <i>Journal of Biological Chemistry</i> , 2013, 288, 30917-30930.	3.4	80
32	Probing the Influence of Citrate-Capped Gold Nanoparticles on an Amyloidogenic Protein. <i>ACS Nano</i> , 2015, 9, 2600-2613.	14.6	80
33	Lysozyme: A paradigmatic molecule for the investigation of protein structure, function and misfolding. <i>Clinica Chimica Acta</i> , 2005, 357, 168-172.	1.1	74
34	Capillary electrophoresis studies on the aggregation process of β 2-amyloid 1-42 and 1-40 peptides. <i>Electrophoresis</i> , 2004, 25, 3186-3194.	2.4	73
35	Systemic Amyloidosis: Lessons from β 2-Microglobulin. <i>Journal of Biological Chemistry</i> , 2015, 290, 9951-9958.	3.4	73
36	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. <i>Gastroenterology</i> , 2004, 126, 1416-1422.	1.3	70

#	ARTICLE	IF	CITATIONS
37	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. <i>Journal of Biological Chemistry</i> , 2018, 293, 14192-14199.	3.4	68
38	Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. <i>British Journal of Haematology</i> , 1990, 74, 65-69.	2.5	65
39	Properties of Some Variants of Human β_2 -Microglobulin and Amyloidogenesis. <i>Journal of Biological Chemistry</i> , 2004, 279, 9176-9189.	3.4	65
40	The H50Q Mutation Induces a 10-fold Decrease in the Solubility of β -Synuclein. <i>Journal of Biological Chemistry</i> , 2015, 290, 2395-2404.	3.4	65
41	Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 7619-7623.	7.1	63
42	The workings of the amyloid diseases. <i>Annals of Medicine</i> , 2007, 39, 200-207.	3.8	62
43	Study of three patients with monoclonal gammopathies and β -lupus-like™ anticoagulants. <i>British Journal of Haematology</i> , 1989, 73, 221-227.	2.5	57
44	β_2 -Microglobulin isoforms display an heterogeneous affinity for type I collagen. <i>Protein Science</i> , 2005, 14, 696-702.	7.6	56
45	4-Iodo-4-Deoxydoxorubicin Disrupts the Fibrillar Structure of Transthyretin Amyloid. <i>American Journal of Pathology</i> , 2000, 156, 1919-1925.	3.8	55
46	Trapping of palindromic ligands within native transthyretin prevents amyloid formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20483-20488.	7.1	55
47	Native-unlike Long-lived Intermediates along the Folding Pathway of the Amyloidogenic Protein β_2 -Microglobulin Revealed by Real-time Two-dimensional NMR. <i>Journal of Biological Chemistry</i> , 2010, 285, 5827-5835.	3.4	55
48	Topological investigation of amyloid fibrils obtained from β_2 -microglobulin. <i>Protein Science</i> , 2009, 11, 2362-2369.	7.6	53
49	Conformational dynamics in crystals reveal the molecular bases for D76N beta-2 microglobulin aggregation propensity. <i>Nature Communications</i> , 2018, 9, 1658.	12.8	53
50	Capillary electrophoresis investigation of a partially unfolded conformation of β_2 -microglobulin. <i>Electrophoresis</i> , 2002, 23, 918-925.	2.4	52
51	Cardiac immunocyte-derived (AL) amyloidosis: An endomyocardial biopsy study in 11 patients. <i>American Heart Journal</i> , 1995, 130, 528-536.	2.7	50
52	D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. <i>Nature Communications</i> , 2016, 7, 10353.	12.8	50
53	Pharmaceutical Strategies Against Amyloidosis: Old and New Drugs in Targeting a Protein Misfolding Disease. <i>Current Medicinal Chemistry</i> , 2004, 11, 1065-1084.	2.4	48
54	Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. <i>Journal of Molecular Biology</i> , 2011, 407, 465-476.	4.2	48

#	ARTICLE	IF	CITATIONS
55	Rational design of mutations that change the aggregation rate of a protein while maintaining its native structure and stability. <i>Scientific Reports</i> , 2016, 6, 25559.	3.3	47
56	A Narrative Review of the Role of Transthyretin in Health and Disease. <i>Neurology and Therapy</i> , 2020, 9, 395-402.	3.2	47
57	The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 145-153.	3.0	46
58	Occurrence of monoclonal components in general practice: Clinical implications. <i>European Journal of Haematology</i> , 1992, 48, 192-195.	2.2	45
59	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. <i>Protein Science</i> , 2001, 10, 187-199.	7.6	44
60	Characterization of apo(a) polymorphism by a modified immunoblotting technique in an italian population sample. <i>Clinica Chimica Acta</i> , 1993, 221, 159-169.	1.1	43
61	DE loop mutations affect β_2 microglobulin stability, oligomerization, and the low pH unfolded form. <i>Protein Science</i> , 2010, 19, 1386-1394.	7.6	43
62	Molecular Dynamics Simulation Suggests Possible Interaction Patterns at Early Steps of β_2 -Microglobulin Aggregation. <i>Biophysical Journal</i> , 2007, 92, 1673-1681.	0.5	39
63	The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies. <i>Journal of Nutritional Biochemistry</i> , 2016, 30, 153-166.	4.2	39
64	Breakdown of supersaturation barrier links protein folding to amyloid formation. <i>Communications Biology</i> , 2021, 4, 120.	4.4	39
65	β_2 -Microglobulin H31Y Variant 3D Structure Highlights the Protein Natural Propensity Towards Intermolecular Aggregation. <i>Journal of Molecular Biology</i> , 2004, 335, 1051-1064.	4.2	38
66	Limited proteolysis in the investigation of β_2 -microglobulin amyloidogenic and fibrillar states. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2005, 1753, 44-50.	2.3	36
67	Proteomics of β_2 -microglobulin amyloid fibrils. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2005, 1753, 23-33.	2.3	36
68	DE loop mutations affect β_2 -microglobulin stability and amyloid aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2008, 377, 146-150.	2.1	36
69	Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease. <i>American Journal of Hematology</i> , 1994, 46, 189-193.	4.1	35
70	Folding and Fibrillogenesis: Clues from β_2 -Microglobulin. <i>Journal of Molecular Biology</i> , 2010, 401, 286-297.	4.2	35
71	Fibrillar vs Crystalline Full-Length β_2 -Microglobulin Studied by High-Resolution Solid-State NMR Spectroscopy. <i>Journal of the American Chemical Society</i> , 2010, 132, 5556-5557.	13.7	32
72	Monitoring the Interaction between β_2 -Microglobulin and the Molecular Chaperone β -crystallin by NMR and Mass Spectrometry. <i>Journal of Biological Chemistry</i> , 2013, 288, 17844-17858.	3.4	32

#	ARTICLE	IF	CITATIONS
73	Î²2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 1176-1181.	0.7	31
74	Molecular dynamics simulation of Î² ₂ -microglobulin in denaturing and stabilizing conditions. <i>Proteins: Structure, Function and Bioinformatics</i> , 2011, 79, 986-1001.	2.6	31
75	Structure, Stability, and Aggregation of Î²-2 Microglobulin Mutants: Insights from a Fourier Transform Infrared Study in Solution and in the Crystalline State. <i>Biophysical Journal</i> , 2012, 102, 1676-1684.	0.5	31
76	Assessment of Cellular Responses after Short- and Long-Term Exposure to Silver Nanoparticles in Human Neuroblastoma (SH-SY5Y) and Astrocytoma (D384) Cells. <i>Scientific World Journal</i> , The, 2014, 2014, 1-13.	2.1	31
77	Î±-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. <i>Journal of Biological Chemistry</i> , 2017, 292, 6927-6937.	3.4	31
78	Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel. <i>Scientific Reports</i> , 2017, 7, 182.	3.3	31
79	Characteristics of a ferritin-binding protein present in human serum. <i>British Journal of Haematology</i> , 1987, 65, 489-493.	2.5	30
80	Citrate stabilized gold nanoparticles interfere with amyloid fibril formation: D76N and Î² ^{N6} Î²2-microglobulin variants. <i>Nanoscale</i> , 2018, 10, 4793-4806.	5.6	30
81	Oleuropein aglycone: A polyphenol with different targets against amyloid toxicity. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 1432-1442.	2.4	30
82	Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1991, 1097, 177-182.	3.8	29
83	Protein Aggregation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2001, 39, 1065-75.	2.3	29
84	Human beta-2 microglobulin W60V mutant structure: Implications for stability and amyloid aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 380, 543-547.	2.1	29
85	Co-fibrillogenesis of Wild-type and D76N Î²2-Microglobulin. <i>Journal of Biological Chemistry</i> , 2016, 291, 9678-9689.	3.4	29
86	Use of Anti-(beta2 Microglobulin) mAb to Study Formation of Amyloid Fibrils. <i>FEBS Journal</i> , 1997, 249, 21-26.	0.2	28
87	Affinity capillary electrophoresis is a powerful tool to identify transthyretin binding drugs for potential therapeutic use in amyloidosis. <i>Electrophoresis</i> , 2000, 21, 3280-3289.	2.4	27
88	Micro-heterogeneity and aggregation in Î²2-microglobulin solutions: effects of temperature, pH, and conformational variant addition. <i>European Biophysics Journal</i> , 2006, 35, 439-445.	2.2	27
89	New drug therapy of amyloidoses: resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin. <i>Blood</i> , 1995, 86, 855-61.	1.4	27
90	Family developmental risk factors among adolescents with disabilities and children of parents with disabilities. <i>Journal of Adolescence</i> , 2007, 30, 1001-1019.	2.4	26

#	ARTICLE	IF	CITATIONS
91	Citrate-stabilized gold nanoparticles hinder fibrillogenesis of a pathological variant of β_2 -microglobulin. <i>Nanoscale</i> , 2017, 9, 3941-3951.	5.6	26
92	Solution structure of β_2 -microglobulin and insights into fibrillogenesis. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2005, 1753, 76-84.	2.3	25
93	Amyloid persistence in decellularized liver: biochemical and histopathological characterization. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016, 23, 1-7.	3.0	25
94	Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8274-8283.	6.4	25
95	Current concepts on the pathogenesis of systemic amyloidosis. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 53-62.	0.7	24
96	Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. <i>Protein Science</i> , 2006, 16, 343-349.	7.6	24
97	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2013, 20, 173-178.	3.0	24
98	Defect of Platelet Aggregation and Adhesion Induced by Autoantibodies Against Platelet Glycoprotein IIIa. <i>Thrombosis and Haemostasis</i> , 1992, 68, 208-213.	3.4	24
99	Immunological Reactivity of Serum Ferritin in Patients with Malignancy. <i>Tumori</i> , 1985, 71, 547-554.	1.1	23
100	Dynamic of β_2 -Microglobulin Fibril Formation and Reabsorption: The Role of β -Proteolysis. <i>Seminars in Dialysis</i> , 2001, 14, 117-122.	1.3	23
101	Structural and Folding Dynamic Properties of the T70N Variant of Human Lysozyme. <i>Journal of Biological Chemistry</i> , 2003, 278, 25910-25918.	3.4	23
102	Molecular insights into cell toxicity of a novel familial amyloidogenic variant of β_2 -microglobulin. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 1443-1456.	3.6	23
103	Detection of fragments of β_2 -microglobulin in amyloid fibrils. <i>Kidney International</i> , 2000, 57, 349-350.	5.2	22
104	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 87-93.	3.8	22
105	Class I Major Histocompatibility Complex, the Trojan Horse for Secretion of Amyloidogenic β_2 -Microglobulin. <i>Journal of Biological Chemistry</i> , 2014, 289, 3318-3327.	3.4	22
106	Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro. <i>Scientific Reports</i> , 2016, 6, 29077.	3.3	22
107	<i>C. elegans</i> Expressing Human β_2 -Microglobulin: A Novel Model for Studying the Relationship between the Molecular Assembly and the Toxic Phenotype. <i>PLoS ONE</i> , 2012, 7, e52314.	2.5	21
108	Equilibrium Unfolding Thermodynamics of β_2 -Microglobulin Analyzed through Native-State H/D Exchange. <i>Biophysical Journal</i> , 2009, 96, 169-179.	0.5	20

#	ARTICLE	IF	CITATIONS
109	L444P Gba1 mutation increases formation and spread of β -synuclein deposits in mice injected with mouse β -synuclein pre-formed fibrils. <i>PLoS ONE</i> , 2020, 15, e0238075.	2.5	20
110	Diagnostic amyloid proteomics: experience of the UK National Amyloidosis Centre. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 948-957.	2.3	20
111	Use of a monoclonal antibody against human heart ferritin for evaluating acidic ferritin concentration in human serum. <i>British Journal of Haematology</i> , 1985, 61, 445-453.	2.5	19
112	Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004, 1690, 33-41.	3.8	19
113	Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue Targeting. <i>Frontiers in Molecular Biosciences</i> , 2016, 3, 17.	3.5	19
114	Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. <i>Biophysical Journal</i> , 2016, 111, 2024-2038.	0.5	19
115	Structural and functional characterization of three human immunoglobulin λ light chains with different pathological implications. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1996, 1317, 161-167.	3.8	18
116	Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. <i>Pharmacological Research</i> , 2004, 50, 419-431.	7.1	18
117	Recombinant amyloidogenic domain of ApoA-I: Analysis of its fibrillogenic potential. <i>Biochemical and Biophysical Research Communications</i> , 2006, 351, 223-228.	2.1	18
118	Sulfonated molecules that bind a partially structured species of β -microglobulin also influence refolding and fibrillogenesis. <i>Electrophoresis</i> , 2008, 29, 1502-1510.	2.4	18
119	A recurrent β -strand association interface is observed in β -microglobulin oligomers. <i>FEBS Journal</i> , 2012, 279, 1131-1143.	4.7	18
120	A specific nanobody prevents amyloidogenesis of D76N β -microglobulin in vitro and modifies its tissue distribution in vivo. <i>Scientific Reports</i> , 2017, 7, 46711.	3.3	18
121	Search of ligands for the amyloidogenic protein β -microglobulin by capillary electrophoresis and other techniques. <i>Electrophoresis</i> , 2005, 26, 4055-4063.	2.4	17
122	Human Lysozyme. , 2007, , 285-308.		17
123	The two tryptophans of β -microglobulin have distinct roles in function and folding and might represent two independent responses to evolutionary pressure. <i>BMC Evolutionary Biology</i> , 2011, 11, 159.	3.2	16
124	Enhanced molecular chaperone activity of the small heat shock protein β -crystallin following covalent immobilization onto a solid-phase support. <i>Biopolymers</i> , 2011, 95, 376-389.	2.4	14
125	Structure of an early native-like intermediate of β -microglobulin amyloidogenesis. <i>Protein Science</i> , 2013, 22, 1349-1357.	7.6	14
126	Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies. <i>Journal of Proteomics</i> , 2017, 165, 113-118.	2.4	14

#	ARTICLE	IF	CITATIONS
127	C. elegans expressing D76N β 2-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis. Scientific Reports, 2019, 9, 19960.	3.3	14
128	Dâ€strand perturbation and amyloid propensity in betaâ€2 microglobulin. FEBS Journal, 2011, 278, 2349-2358.	4.7	13
129	Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis.. Journal of the American Society of Nephrology: JASN, 1995, 6, 1262-1270.	6.1	13
130	Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis. Nature Communications, 2021, 12, 7112.	12.8	13
131	Structural characterization of β II Inc, a new amyloid immunoglobulin. BBA - Proteins and Proteomics, 1989, 995, 103-108.	2.1	12
132	Comparative study of the stabilities of synthetic in vitro and natural ex vivo transthyretin amyloid fibrils. Journal of Biological Chemistry, 2020, 295, 11379-11387.	3.4	12
133	Identification and characterization of a new ligand-binding site in FnBB, a fibronectin-binding adhesin from Streptococcus dysgalactiae. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1646, 173-183.	2.3	11
134	Interference of citrate-stabilized gold nanoparticles with β 2-microglobulin oligomeric association. Chemical Communications, 2018, 54, 5422-5425.	4.1	11
135	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
136	Reduction of conformational mobility and aggregation in W60G β 2-microglobulin: assessment by ¹⁵ N NMR relaxation. Magnetic Resonance in Chemistry, 2013, 51, 795-807.	1.9	10
137	Use of an Anti-Idiotypic Monoclonal Antibody in Studying Amyloidogenic Light Chains in Cells, Urine and Fibrils: Pathophysiology and Clinical Implications. Scandinavian Journal of Immunology, 1992, 36, 607-616.	2.7	9
138	The effects of an ideal β -turn on β -2 microglobulin fold stability. Journal of Biochemistry, 2011, 150, 39-47.	1.7	9
139	Determining the Energy Landscape of Proteins by a Fast Isotope Exchange NMR Approach. Journal of the American Chemical Society, 2012, 134, 4457-4460.	13.7	9
140	Enhanced toxicity of silver nanoparticles in transgenic <i>Caenorhabditis elegans</i> expressing amyloidogenic proteins. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 221-228.	3.0	9
141	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	2.3	8
142	Pathological Self-Aggregation of β 2-Microglobulin: A Challenge for Protein Biophysics. Sub-Cellular Biochemistry, 2012, 65, 165-183.	2.4	8
143	Fibrillogenesis of human β 2-microglobulin in three-dimensional silicon microstructures. Journal of Biophotonics, 2012, 5, 785-792.	2.3	8
144	Misidentification of transthyretin and immunoglobulin variants by proteomics due to methyl lysine formation in formalin-fixed paraffin-embedded amyloid tissue. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 229-237.	3.0	8

#	ARTICLE	IF	CITATIONS
145	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 1708-1711.	0.7	7
146	Single-shot NMR measurement of protein unfolding landscapes. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2012, 1824, 842-849.	2.3	7
147	The interaction of β 2-microglobulin with gold nanoparticles: impact of coating, charge and size. <i>Journal of Materials Chemistry B</i> , 2018, 6, 5964-5974.	5.8	7
148	Lysozyme amyloid: evidence for the W64R variant by proteomics in the absence of the wild type protein. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 206-207.	3.0	6
149	Characterization of the Two Unique Human Anti-Flavin Monoclonal Immunoglobulins. <i>FEBS Journal</i> , 1995, 228, 886-893.	0.2	6
150	Selective bone marrow involvement of lymphoplasmacytic cells secreting monoclonal IgA rheumatoid factor in a patient with Sjogren's syndrome and serum hyperviscosity.. <i>Annals of the Rheumatic Diseases</i> , 1987, 46, 938-942.	0.9	5
151	Immunobiology and pathogenesis of hepatitis C virus infection. <i>Research in Virology</i> , 1993, 144, 269-274.	0.7	5
152	Hepatitis C virus-associated cryoglobulinaemic glomerulonephritis with delayed appearance of monoclonal cryoglobulinaemia. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 432-434.	0.7	5
153	Preliminary crystallographic characterization of the human β 2 microglobulin His31Tyr mutant in a tetrameric assembly. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2003, 59, 1270-1272.	2.5	5
154	Lysozyme. , 0, , 635-656.		5
155	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 115-121.	3.0	5
156	Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres. <i>Molecules</i> , 2021, 26, 1913.	3.8	5
157	The corona of protein-gold nanoparticle systems: the role of ionic strength. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 1630-1637.	2.8	5
158	Conformational dynamics of the β 2-microglobulin C terminal in the cell-membrane-anchored major histocompatibility complex type I. <i>Cellular and Molecular Life Sciences</i> , 2000, 57, 675-683.	5.4	4
159	Short-Chain Alkanethiol Coating for Small-Size Gold Nanoparticles Supporting Protein Stability. <i>Magnetochemistry</i> , 2017, 3, 40.	2.4	4
160	Clinical ApoAIV amyloid is associated with fibrillogenic signal sequence. <i>Journal of Pathology</i> , 2021, 255, 311-318.	4.5	4
161	Molecular Mechanisms of Fibrillogenesis and the Protective Role of Amyloid P Component: Two Possible Avenues for Therapy. <i>Novartis Foundation Symposium</i> , 1996, 199, 73-103.	1.1	4
162	Toward understanding the molecular pathogenesis of monoclonal immunoglobulin light-chain deposition. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 1708-1711.	0.7	3

#	ARTICLE	IF	CITATIONS
163	Embryonic stem and haematopoietic progenitor cells resist to A β oligomer toxicity and maintain the differentiation potency in culture. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2010, 17, 137-145.	3.0	3
164	Antiamyloidogenic and proamyloidogenic chaperone effects of C-reactive protein and serum amyloid P component. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 28-29.	3.0	3
165	Smart conservation for the lazy consumer [Tech Life]. <i>IEEE Spectrum</i> , 2012, 49, 26-30.	0.7	2
166	Bifunctional crosslinking ligands for transthyretin. <i>Open Biology</i> , 2015, 5, 150105.	3.6	2
167	An Asp to Asn mutation is a toxic trigger in beta-2 microglobulin: structure and biophysics. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 15-16.	3.0	2
168	Application of Monoclonal Anti-idiotypes in the Study of AL Amyloidosis: Therapeutic Implications. <i>Renal Failure</i> , 1993, 15, 365-371.	2.1	1
169	Protein aggregation. <i>International Journal of Biological Macromolecules</i> , 2017, 100, 1-2.	7.5	1
170	Topologically non-trivial metal-organic assemblies inhibit β 2-microglobulin amyloidogenesis. <i>Cell Reports Physical Science</i> , 2021, 2, 100477.	5.6	1
171	A Case of IgM(λ) Monoclonal Gammopathy Simulating an IgM-IgG Biclonal Gammopathy. <i>Annals of Clinical Biochemistry</i> , 1990, 27, 158-160.	1.6	0
172	Dialysis-related amyloidosis: From molecular mechanism to therapies. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2005, 1753, 1-3.	2.3	0
173	Nanotechnology drives a paradigm shift on protein misfolding diseases and amyloidosis. , 2012, , .		0
174	AA amyloidosis without systemic inflammation: when clinical evidence validates predictions of experimental medicine. <i>Kidney International</i> , 2022, 101, 219-221.	5.2	0
175	Title is missing!. , 2020, 15, e0238075.		0
176	Title is missing!. , 2020, 15, e0238075.		0
177	Title is missing!. , 2020, 15, e0238075.		0
178	Title is missing!. , 2020, 15, e0238075.		0
179	Immunoassay methods for determination of serum C-reactive protein levels. <i>Research in Clinic and Laboratory</i> , 1984, 14, 581-585.	0.3	0